Founded in December 2000 and based in Shanghai, WuXi (pronounced Woo-See) PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. WuXi PharmaTech offers global pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and manufacturing services ranging from discovery chemistry to biological services and manufacturing of APIs for R&D use.
WuXi PharmaTech assists its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions. The management team consists of Western-trained Ph.D.s and MBAs with experience in drug R&D methodologies and Western-style business practices. Collectively, senior management has more than 100 patents pending or granted, published more than 500 publications and has an average of 10 years of experience working in major international pharmaceutical and biotechnology companies.
With over 1,300 scientific staff members, a 630,000 sq. ft. Shanghai Waigaoqiao Free Trade Zone research facility, a 220,000 sq. ft. cGMP-quality manufacturing plant in Jinshan District, Shanghai, and a new 130,000 sq. ft. Tianjin research facility, WuXi PharmaTech is well-positioned to offer its customers high quality services along the drug discovery value chain. In 2006, WuXi PharmaTech's customers included 9 of the top 10 pharmaceutical companies in the world, as measured by 2006 total revenues.
That's the blurb. Listing on the NYSE August 9th 2007 this company is the latest entry in to the round of "Stocks Gone Wild" emanating from China. Our position in this company is "as listed" a short term trading play, and as the stock advances we will be using a 20% trailing stop to minimize our risk and remove emotion. This gives us the greatest potential for upside movement while minimizing our short term risks and preserving capital assets. With the latest run up in investments in the far east, a declining dollar at home and the crunch of a slowing economy we see natural money flows heading toward these types of speculative risks based investments.
With recent news stories such as Piper Jaffray comments on LDK Solar (LDK) the concerns of valuation and accounting standards in the course of the next 6-8 months will grow exponentially as we reached the touted date of 8-8-8. What appears to be lining up as a classic value trap for date setting on investments. the smart money will be exiting possibly 3 to 4 months early. We do not plan on being invested then either, as the safe money will take profits and seek investments in safer harbors.
Declines in this type of investment of newly funded, foreign market momentum trades are likely to loose value. As a responsible individual and not an investment adviser I would leave you with this word of
CAUTION: Investments in this type of stock can be hazardous to your wealth. We recommend consulting a certified or professional investment adviser before executing trades or considering a position in any form of financial instrument. There is no substitute for through research and analysis. As your mother may have told you "Do Your homework" life is a continuous learning lesson.
WuXi PharmaTech assists its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions. The management team consists of Western-trained Ph.D.s and MBAs with experience in drug R&D methodologies and Western-style business practices. Collectively, senior management has more than 100 patents pending or granted, published more than 500 publications and has an average of 10 years of experience working in major international pharmaceutical and biotechnology companies.
With over 1,300 scientific staff members, a 630,000 sq. ft. Shanghai Waigaoqiao Free Trade Zone research facility, a 220,000 sq. ft. cGMP-quality manufacturing plant in Jinshan District, Shanghai, and a new 130,000 sq. ft. Tianjin research facility, WuXi PharmaTech is well-positioned to offer its customers high quality services along the drug discovery value chain. In 2006, WuXi PharmaTech's customers included 9 of the top 10 pharmaceutical companies in the world, as measured by 2006 total revenues.
That's the blurb. Listing on the NYSE August 9th 2007 this company is the latest entry in to the round of "Stocks Gone Wild" emanating from China. Our position in this company is "as listed" a short term trading play, and as the stock advances we will be using a 20% trailing stop to minimize our risk and remove emotion. This gives us the greatest potential for upside movement while minimizing our short term risks and preserving capital assets. With the latest run up in investments in the far east, a declining dollar at home and the crunch of a slowing economy we see natural money flows heading toward these types of speculative risks based investments.
With recent news stories such as Piper Jaffray comments on LDK Solar (LDK) the concerns of valuation and accounting standards in the course of the next 6-8 months will grow exponentially as we reached the touted date of 8-8-8. What appears to be lining up as a classic value trap for date setting on investments. the smart money will be exiting possibly 3 to 4 months early. We do not plan on being invested then either, as the safe money will take profits and seek investments in safer harbors.
Declines in this type of investment of newly funded, foreign market momentum trades are likely to loose value. As a responsible individual and not an investment adviser I would leave you with this word of
CAUTION: Investments in this type of stock can be hazardous to your wealth. We recommend consulting a certified or professional investment adviser before executing trades or considering a position in any form of financial instrument. There is no substitute for through research and analysis. As your mother may have told you "Do Your homework" life is a continuous learning lesson.
No comments:
Post a Comment